CANTICANTI home
Back to diseases

Disease hub

Multiple Myeloma

Open Targets catalogue label: multiple myeloma

Structured disease–target and disease–drug rows, trial registry mirrors, and linked research signals appear here when they are indexed to this hub key. Sparse pages are expected for newer routes — this is not a claim about biological evidence absence.

Data: Live structured evidence (Supabase)

Source catalogue
—
Imported rows
—
Explorer-eligible
—
Targets w/ drugs
—
Open guided lookup (general disease context)
Also indexed as

multiple myeloma · EFO_0001378 · multiple myeloma, resistance to, Somatic mutation · myeloma · Kahler disease · medullary plasmacytoma · myeloma, plasma cell, malignant · plasma cell myeloma · multiple myeloma, susceptibility to, Somatic mutation · plasma cell myeloid neoplasm · myelomatosis · myeloid neoplasm of plasma cell · multiple myeloma/plasma cell myeloma · Kahler's disease · myeloma, multiple · myeloma - multiple · Al amyloidosis · amyloidosis, systemic · COHD:437233 · ICD9:203.0 · UMLS:C0026764 · EFO:0001378 · ICD10:C90.00 · MedDRA:10028228 · ONCOTREE:PCM · NCIT:C3242 · GARD:0007108 · NORD:1469 · MESH:D009101 · MONDO:0009693 · icd11.foundation:1582389689 · ICDO:9732/3 · icd11.foundation:526287100 · GARD:7108 · DOID:9538 · MEDGEN:10122 · Orphanet:29073 · OMIM:254500 · ICD10CM:C90.0 · ICD10:C90.0

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Disease–target coverage
Coverage metrics for this hub when live evidence-graph and catalogue snapshots are available.
Source catalogue associations
—

Open Targets associated-target catalogue count for this disease node — not clinically ranked, validated, or treatment-linked targets.

Imported evidence rows
—

Source evidence rows, not unique targets.

Explorer-eligible targets
—

Targets in the GBM evidence-graph view with default dashboard eligibility.

Targets with drug relationships
—

Distinct active GBM explorer-eligible targets with drug–target mechanism-of-action relationships (disease-scoped; not a global catalogue count).

Disease-linked drugs
—

Unique active drugs linked to this disease in the evidence graph.

Disease-drug evidence edges
—

Active disease–drug evidence edges (methodology detail).

Catalogue and row counts are research inventory signals. They do not mean every association is clinically relevant, validated, druggable, or treatment-linked.